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a b s t r a c t 
Alzheimer’s disease (AD) is the most common form of dementia and is phenotypically heterogeneous. APOE is a 
triallelic gene which correlates with phenotypic heterogeneity in AD. In this work, we determined the effect of 
APOE alleles on the disease progression timeline of AD using a discriminative event-based model (DEBM). Since 
DEBM is a data-driven model, stratification into smaller disease subgroups would lead to more inaccurate models 
as compared to fitting the model on the entire dataset. Hence our secondary aim is to propose and evaluate novel 
approaches in which we split the different steps of DEBM into group-aspecific and group-specific parts, where 
the entire dataset is used to train the group-aspecific parts and only the data from a specific group is used to 
train the group-specific parts of the DEBM. We performed simulation experiments to benchmark the accuracy of 
the proposed approaches and to select the optimal approach. Subsequently, the chosen approach was applied to 
the baseline data of 417 cognitively normal, 235 mild cognitively impaired who convert to AD within 3 years, 
and 342 AD patients from the Alzheimers Disease Neuroimaging Initiative (ADNI) dataset to gain new insights 
into the effect of APOE carriership on the disease progression timeline of AD. In the 𝜀 4 carrier group, the model 
predicted with high confidence that CSF Amyloid 𝛽42 and the cognitive score of Alzheimer’s Disease Assessment 
Scale (ADAS) are early biomarkers. Hippocampus was the earliest volumetric biomarker to become abnormal, 
closely followed by the CSF Phosphorylated Tau 181 (PTAU) biomarker. In the homozygous 𝜀 3 carrier group, the 
model predicted a similar ordering among CSF biomarkers. However, the volume of the fusiform gyrus was 
identified as one of the earliest volumetric biomarker. While the findings in the 𝜀 4 carrier and the homozygous 
𝜀 3 carrier groups fit the current understanding of progression of AD, the finding in the 𝜀 2 carrier group did not. 
The model predicted, with relatively low confidence, CSF Neurogranin as one of the earliest biomarkers along 
with cognitive score of Mini-Mental State Examination (MMSE). Amyloid 𝛽42 was found to become abnormal 
after PTAU. The presented models could aid understanding of the disease, and in selecting homogeneous group 





















Dementia affects roughly 5% of the world’s elderly population of
hom 60 − 70% are affected by Alzheimer’s Disease (AD), which is the
ost common form of dementia ( Organization, 2017 ). There are several
eurobiological subtypes of AD ( Ferreira et al., 2020 ) and each subtype
otentially needs a different strategy to prevent or slow the progression∗ Corresponding author. 
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rucial for selecting novel preventive or therapeutic targets for clinical
rials of disease modifying treatments, identifying target groups for such
rials and tracking the disease progression in patients. 
While several studies have looked into the pathophysiology of
D ( Bloom, 2014; Jack Jr. et al., 2013; Weigand et al., 2019 ), it is
till not completely understood. Although it has been observed that ADase Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the 
NI and/or provided data but did not participate in analysis or writing of this 
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Fig. 1. Overview of the steps involved in DEBM. Input for the DEBM model is a cross-sectional dataset 𝑋 with 𝑀 subjects and various biomarkers ( 𝐴, 𝐵, 𝐶 and 𝐷) 
representing different aspects of neuro-degeneration. Using Gaussian mixture modeling (GMM), mixing parameters ( 𝜃𝑖 ) and probability density functions of normal 
( 𝑝 ( 𝑥 ⋅,𝑖 |¬𝐸 𝑖 )) and abnormal ( 𝑝 ( 𝑥 ⋅,𝑖 |𝐸 𝑖 )) levels are estimated for each biomarker. This is followed by the estimation of subject-specific orderings ( 𝑠 𝑗 ) , for each subject in 
the dataset. Disease progression timeline consisting of central ordering ( 𝑆) and event-centers ( 𝜆) are estimated based on these subject-specific orderings. Based on 




























































































W  s phenotypically heterogeneous ( Au et al., 2015; Murray et al., 2011;
atterson, 2018 ) with potentially different pathways for disease progres-
ion, these pathways remain unclear. There is hence a need to under-
tand the phenotypic heterogeneity in AD while leveraging neuroimag-
ng, fluid and cognitive biomarkers. 
APOE is a triallelic gene in which the 𝜀 2 allele reduces the risk of
D ( van der Lee et al., 2018 ), the 𝜀 3 allele acts as a reference allele and
he 𝜀 4 allele is a major genetic risk factor of AD ( Genin et al., 2011; Kim
t al., 2009; Saunders et al., 1993 ). APOE has been shown to correlate
ith phenotypic heterogeneity in AD ( Weintraub et al., 2019 ). Hence we
ypothesize that the pathophysiology of AD can be better understood
hen considering the effect of APOE carriership on biomarker changes.
In the context of data-driven methods for understanding AD patho-
hysiology, disease progression models have been used to study the tra-
ectories of individual biomarkers ( Jedynak et al., 2012; Lorenzi et al.,
019; Schiratti et al., 2015 ) as well as their progression with respect to
ach other ( Fonteijn et al., 2012; Huang and Alexander, 2012; Venka-
raghavan et al., 2017; Young et al., 2014 ). Unlike typical machine
earning approaches, these models are interpretable by design and pro-
ide insight for understanding the mechanisms of disease progression.
vent-based models (EBMs) are a class of such interpretable disease pro-
ression models that estimate the timeline of neuropathologic change
uring AD progression using cross-sectional data ( Fonteijn et al., 2012;
enkatraghavan et al., 2019a ). 
Our primary aim is to use the discriminative event-based model
DEBM), which was shown to be more accurate than previously pro-
osed EBMs ( Venkatraghavan et al., 2019a ), to understand the effect of
ifferent APOE alleles on the disease timeline of AD. To shed light on
ifferent aspects of neurodegeneration and identify the earliest brain
egions affected, we included commonly studied cerebrospinal fluid
CSF) biomarkers, cognitive scores, and volumetric biomarkers from
euroimaging. 
The default approach for estimating the disease progression timeline
ould be to stratify the population based on their APOE 𝜀 2 − 4 carrier
tatus and independently train the DEBM model on the stratified pop-
lations ( Young et al., 2014 ). However, since DEBM is a data-driven
odel, stratification into smaller groups would lead to less accurate
odels than those obtained by the original method on the entire dataset.
ence our secondary aim is to propose and evaluate a novel approach
n which we split the different steps of DEBM into group-aspecific and
roup-specific parts, where the entire dataset is used to train the group-
specific parts and only the data from a specific group is used to train the
roup-specific parts of the DEBM. We present two different variations
f this approach and we hypothesize that the optimal split of the DEBM
teps into the group-aspecific and group-specific parts would result in
etter accuracy of the estimated disease progression timeline. Since the
round-truth timelines are unknown in a clinical setting, we evaluate
he accuracy of the proposed variations using simulation experiments
nd we select the optimal method for the analysis on the effect of APOE
n the AD progression timeline on patient data. 
d
2 To summarize, our contributions in this paper include proposing and
valuating a novel approach for using DEBM in stratified populations
nd estimating a comprehensive timeline of AD progression, in terms of
iomarker changes, in the presence of different APOE alleles. 
. Methods 
An introduction to the DEBM model ( Venkatraghavan et al., 2019a )
s provided in Section 2.1 . In Section 2.2 we propose our novel approach
or using DEBM in stratified populations with its two variations. 
.1. Discriminative event-based modeling 
In a cross-sectional dataset ( 𝑋) of 𝑀 subjects, including cogni-
ively normal individuals (CN), subjects with mild cognitive impairment
MCI) and patients with AD, let 𝑋 𝑗 denote a measurement of biomark-
rs for subject 𝑗 ∈ [ 1 , 𝑀 ] , consisting of scalar biomarker values 𝑥 𝑗,𝑖 for
 ∈ [ 1 , 𝑁 ] . 𝑥 ⋅,𝑖 denotes the 𝑖 th biomarker for any unspecified 𝑗. DEBM
stimates the posterior probabilities of individual biomarkers being ab-
ormal. These posterior probabilities are used to estimate the ordering
f biomarker changes for each subject independently. The central order-
ng and disease progression timeline for the entire dataset are estimated
ased on these subject-specific orderings. The resulting disease progres-
ion timeline is used for assessing the severity of disease in an individual
ased on his/her biomarker values. Figure 1 shows the different steps
nvolved in DEBM. 
Step 1 - Mixture Modeling: As AD is characterized by a cascade
f neuropathological changes that occurs over several years, presymp-
omatic CN subjects can have some abnormal biomarker values. On the
ther hand, in some clinically diagnosed AD subjects, a proportion of
iomarkers may still have normal values, as they might not have an un-
erlying AD pathology or could have atypical AD. Hence clinical labels
annot directly be propagated to individual biomarkers to label nor-
al and abnormal biomarker values. We shall refer to this as biomarker
abel noise in the rest of the paper. In order to estimate the posterior
robabilities of individual biomarkers being abnormal, DEBM, similar
o previously proposed EBMs ( Fonteijn et al., 2012; Huang and Alexan-
er, 2012; Young et al., 2014 ), fits a Gaussian mixture model (GMM)
o construct the normal / pre-event probability density function (PDF),
 ( 𝑥 ⋅,𝑖 |¬𝐸 𝑖 ) , and abnormal / post-event PDF, 𝑝 ( 𝑥 ⋅,𝑖 |𝐸 𝑖 ) . Event 𝐸 𝑖 in this
otation is used to denote the corresponding biomarker becoming ab-
ormal and ¬𝐸 𝑖 denotes the corresponnding biomarer being normal. The
forementioned PDFs can be expressed as : 
 ( 𝑥 ⋅,𝑖 |¬𝐸 𝑖 ) =  ( 𝜇𝑖, ¬𝐸 ; 𝜎𝑖, ¬𝐸 ) (1)
 ( 𝑥 ⋅,𝑖 |𝐸 𝑖 ) =  ( 𝜇𝑖,𝐸 ; 𝜎𝑖,𝐸 ) (2)
here,  ( ⨘ , ∫ ) is the normal distribution with mean 𝜇 and standard
eviation 𝜎. 
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Fig. 3. Overview of GMM optimization strategies in the different approaches 
for DEBM analysis in stratified populations. (a) The default approach in which 
GMM in each group is trained independently. (b) GMM in coupled DEBM, where 
the different groups share the Gaussian parameters, but the mixing parameters 
are estimated independently. (c) GMM in co-init DEBM in which the different 
groups are jointly initialized before the GMM optimization, but the optimization 










For estimating these parameters robustly in the presence of
iomarker label noise, the normal and abnormal PDF estimates are first
nitialized using the mean and standard deviations after truncating the
verlapping tails of the observed distributions in CN and AD subjects.
his can be observed in Fig. 2 , where the initialization is performed only
ased on the non-overlapping parts of green and red curves, while the
verlapping part is left out to account for biomarker label noise. At this
tage of GMM initialization, MCI subjects are left out as well, because
t is unsure a priori whether their biomarkers are normal or abnormal.
he resulting initialized PDFs are denoted as ̂𝑝 ( 𝑥 ⋅,𝑖 |¬𝐸 𝑖 ) ) and ̂𝑝 ( 𝑥 ⋅,𝑖 |𝐸 𝑖 ) . 
This is followed by an alternating GMM maximum likelihood op-
imization scheme until both the Gaussian parameters as well as the
ixing parameters converge. All the subjects, including MCI, are used
or GMM optimization. After convergence, these Gaussians are used to
epresent the PDFs 𝑝 ( 𝑥 ⋅,𝑖 |¬𝐸 𝑖 ) and 𝑝 ( 𝑥 ⋅,𝑖 |𝐸 𝑖 ) . The mixing parameters ( 𝜃𝑖 )
re used as prior probabilities to convert these PDFs to posterior prob-
bilities 𝑝 (¬𝐸 𝑖 |𝑥 ⋅,𝑖 ) and 𝑝 ( 𝐸 𝑖 |𝑥 ⋅,𝑖 ) . Fig. 2 shows an overview of this opti-
ization scheme . 
Step 2 - Subject-specific Orderings: 𝑝 ( 𝐸 𝑖 |𝑥 𝑗,𝑖 )∀𝑖 are used to estimate
he subject-specific orderings 𝑠 𝑗 . 𝑠 𝑗 is established such that: 
 𝑗 ∋ 𝑝 
(
𝐸 𝑠 𝑗 ( 1 ) 
|||𝑥 𝑗,𝑠 𝑗 ( 1 ) 
)
> ... > 𝑝 
(
𝐸 𝑠 𝑗 ( 𝑁 ) 
|||𝑥 𝑗,𝑠 𝑗 ( 𝑁 ) 
)
(3) 
Step 3 - Central Ordering: DEBM computes the central event order-
ng 𝑆 from the subject-specific estimates 𝑠 𝑗 . To describe the distribution
f 𝑠 𝑗 , a generalized Mallows model is used ( Fligner and Verducci, 1988 ).
he central ordering is defined as the ordering that minimizes the sum of
istances to all subject-specific orderings 𝑠 𝑗 , with probabilistic Kendall’s
au being the distance measure ( Venkatraghavan et al., 2019a ). While 𝑆
enotes the sequence of biomarker events, the relative position of these
vents (event-centers) in a normalized scale of [ 0 , 1 ] is denoted by the
ector 𝜆. The pair { 𝑆, 𝜆} together forms a disease progression timeline.
Step 4 - Patient Staging: Once the disease progression timeline is
reated, subjects in an independent test set ( 𝑇 ) can be placed on this
imeline to estimate disease severity. This is achieved by converting the
iomarker values of the test subjects to posterior probabilities 𝑝 ( 𝐸 𝑖 |𝑥 𝑗,𝑖 ) ,
𝑗 ∈ 𝑇 . These can be used to estimate disease severities in test subjects
y first estimating the conditional distribution 𝑝 ( 𝑖 |𝑆, 𝑋 𝑗 ) , which esti-
ates the probability that the first 𝑖 events of 𝑆 have occurred for a
est-subject and the rest are yet to occur. 
 
(
𝑖 |𝑆, 𝑋 𝑗 ) ∝ ∏𝑖 𝑙=1 𝑝 (𝐸 𝑆 ( 𝑙 ) |||𝑥 𝑗,𝑆 ( 𝑙 ) 
)
× 𝑁 ∏
𝑙= 𝑖 +1 
𝑝 
(
‶𝐸 𝑆 ( 𝑙 ) 
|||𝑥 𝑗,𝑆 ( 𝑙 ) 
)
(4) 
The patient stage of a test subject ( Υ𝑗 ) is defined as the expectation
f 𝜆( 𝑖 ) with respect to the conditional distribution 𝑝 ( 𝑖 |𝑆, 𝑋 𝑗 ) . 
𝑗 = 
∑𝑁 
𝑖 =1 𝜆( 𝑖 ) 𝑝 ( 𝑖 |𝑆, 𝑋 𝑗 ) ∑𝑁 
𝑖 =1 𝑝 ( 𝑖 |𝑆, 𝑋 𝑗 ) (5)
.2. Group-specific and group-aspecific parts of DEBM 
We propose extensions of DEBM for stratified populations, i.e., when
he dataset 𝑋 can be subdivided in groups 𝑔 ∈ [ 1 , 𝐺 ] , based on, e.g.,
enotype or phenotype of the subjects. Since DEBM is a data-driven
odel, data stratification into smaller groups would lead to more inac-
urate models ( Venkatraghavan et al., 2019a ). To obtain better DEBM
ccuracies in such scenario, we propose to co-train DEBM for estimating
isease timelines ∀𝑔 by splitting DEBM into group-aspecific and group-
pecific parts. The group-aspecific parts of DEBM are estimated using3 he entire dataset and group-specific parts are estimated for each group
ndependently. 
We first discuss the default way of independently training DEBM
n the different groups and then propose two different approaches for
plitting DEBM into group-aspecific and group-specific parts. 
Approach 1: Independent DEBM 
In this default approach, each group is considered as an independent
ataset and the disease progression timeline in each group is estimated
ndependently. GMM in such a scenario is illustrated in Fig. 3 a. 
Approach 2: Coupled DEBM 
EBM →
{ 
𝑝 ( 𝑥 ⋅,𝑖 |¬𝐸 𝑖 ) , 𝑝 ( 𝑥 ⋅,𝑖 |𝐸 𝑖 ) group-aspecific 
𝜃𝑖,𝑔 , { 𝑆 𝑔 , 𝜆𝑔 } , group-specific 
(6) 















































































































both 𝜀 2 and 𝜀 4 alleles 
2 The ADNI was launched in 2003 as a public-private partnership, led by Prin- 
cipal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been 
to test whether serial magnetic resonance imaging (MRI), positron emission to- 
mography (PET), other biological markers, and clinical and neuropsychological 
assessment can be combined to measure the progression of mild cognitive im- 
pairment (MCI) and early Alzheimers disease (AD). For up-to-date information, 
see www.adni-info.org . n this approach, we assume that the different groups share the normal
nd abnormal PDFs, but the ordering in which these biomarkers become
bnormal are different. The mixing parameters ( 𝜃𝑖,𝑔 ) are considered as
roup-specific part of the DEBM algorithm because the proportion of
ubjects with normal and abnormal biomarker values in each group 𝑔
s correlated with the position of the biomarker along the ordering 𝑆 𝑔 ,
hich we expect to be different in each group. 
Hence, in our approach, we modify the alternating GMM opti-
ization scheme to jointly optimize the GMM parameters of multiple
roups. First, the GMM algorithm is initialized without considering the
roups, as explained in Section 2.1 . Secondly, as with the default DEBM,
aussian parameters and mixing parameters are alternately optimized.
n contrast in coupled DEBM, the Gaussian parameters are estimated
ointly for all groups, while mixing parameters are estimated separately
or each group. This has been illustrated in Figure 3 b. 
Once the GMM optimization has been performed, 𝑆 𝑔 and 𝜆𝑔 are es-
imated in each group. Patient staging (Υ𝑗 ) of the test-subjects in group
are computed based on the disease progression timeline { 𝑆 𝑔 , 𝜆𝑔 } . 
Approach 3: Co-init DEBM 
EBM →
⎧ ⎪ ⎨ ⎪ ⎩ 
𝑝 ( 𝑥 ⋅,𝑖 |¬𝐸 𝑖 ) , ̂𝑝 ( 𝑥 ⋅,𝑖 |𝐸 𝑖 ) group-aspecific 
𝑝 𝑔 ( 𝑥 ⋅,𝑖 |¬𝐸 𝑖 ) , 𝑝 𝑔 ( 𝑥 ⋅,𝑖 |𝐸 𝑖 ) group-specific 
𝜃𝑖,𝑔 , { 𝑆 𝑔 , 𝜆𝑔 } group-specific 
(7) 
In this approach, we assume that the different groups do not share
he normal and abnormal PDFs, but that they are close to each other.
ence, in co-init DEBM, we relax the constraint on 𝑝 ( 𝑥 ⋅,𝑖 |¬𝐸 𝑖 ) and
 ( 𝑥 ⋅,𝑖 |𝐸 𝑖 ) and instead consider the initialized values of normal and abnor-
al PDFs ( ̂𝑝 ( 𝑥 ⋅,𝑖 |¬𝐸 𝑖 ) and ̂𝑝 ( 𝑥 ⋅,𝑖 |𝐸 𝑖 ) ) to be group-aspecific part of DEBM.
e estimate 𝑝 𝑔 ( 𝑥 ⋅,𝑖 |¬𝐸 𝑖 ) and 𝑝 𝑔 ( 𝑥 ⋅,𝑖 |𝐸 𝑖 ) independently for each group.
his is illustrated in Fig. 3 c. 
As with the previous approach, 𝑆 𝑔 , 𝜆𝑔 and the patient staging of the
est-subjects in group 𝑔 are computed independently for each group. 
. Experiments 
Section 3.1 describes the experiments to evaluate the proposed
EBM approaches on a stratified population. Since ground-truth order-
ngs are unknown in real clinical data, we use simulated datasets for
valuating the methods. After evaluating the proposed approaches, we
elect the best approach for analyzing the effect of APOE on AD progres-
ion using subjects from the Alzheimer’s Disease Neuroimaging Initia-
ive (ADNI) database. Section 3.2 descibes the details of these experi-
ents. 
.1. Simulation experiments 
We used the framework developed by Young et al. (2015) for simu-
ating cross-sectional data consisting of scalar biomarker values for CN,
CI and AD subjects in two groups. In this framework, disease progres-
ion in a subject is modeled by a series of biomarker changes repre-
enting the temporal cascade of biomarker abnormality as estimated by
n EBM. Individual biomarker trajectories are represented by sigmoids
arying from the biomarker’s normal value to its abnormal value. To ac-
ount for inter-subject variability, the normal and abnormal values for
ifferent subjects are drawn randomly from Gaussian distributions. 
The simulation dataset used in our experiments are based on a
et of seven biomarkers as described in the simulation experiments
f Venkatraghavan et al. (2019a) . The simulated datasets were strati-
ed into two groups, with each group having its own distinct disease
rogression patterns. There are two ways in which the progression of
isease in the groups can differ: 1. difference in ground-truth orderings
 1 and 𝑆 2 ; 2. difference in the abnormal biomarker PDFs in the two
roups i.e. 𝑝 1 ( 𝑥 ⋅,𝑖 |𝐸 𝑖 ) and 𝑝 2 ( 𝑥 ⋅,𝑖 |𝐸 𝑖 ) . Each of these differences could af-
ect the accuracy of the proposed approaches. Hence, we evaluated the
roposed approaches in the presence of each of these differences. Nor-
alized Kendall’s Tau distance between the estimated ordering ( 𝑆) and4 he ground-truth ordering ( 𝑆 𝑔𝑡 ) was used as an evaluation measure in
hese experiments: 
 𝑆 = 
𝐾( 𝑆, 𝑆 𝑔𝑡 ) (𝑁 
2 
) (8)
here 𝐾( 𝐴, 𝐵) is the number of swaps required to obtain ordering B
rom ordering A. 
The normalization ensures that 𝜀 𝑆 falls in the range [ 0 , 1 ] , with 0 as
he distance when the two orderings are the same, and 1 as the distance
hen the two orderings are the reverse of each other. 
Experiment 1: The first simulation experiment studied the effect of
he difference in ordering between the two groups. The ordering in the
rst group (Group 1) was fixed and the ordering in the second group
Group 2) was selected randomly such that the normalized Kendall’s
au distance between the two groups was a fixed number, say 𝜀 𝑂 . 𝜀 𝑂 
as varied from 0 to 1 in steps of 0.2. The number of subjects in Group
 was kept constant at 900. The number of subjects in Group 1 was
aried from 100 to 900 in steps of 200, to study how the different ap-
roaches perform in small as well as large groups. The normal and ab-
ormal biomarkers levels in the two groups were sampled from the same
aussian distribution for this experiment. We generated 50 random rep-
titions of the simulated datasets, and reported mean and standard de-
iation of 𝜀 𝑆 for independent DEBM, coupled DEBM, and co-init DEBM
n groups 1 and 2. 
Experiment 2: This experiment studied the performance of the pro-
osed approaches with the 𝜇𝑔,𝑖,𝐸 parameter of the 𝑝 𝑔 ( 𝑥 ⋅,𝑖 |𝐸 𝑖 ) distribution
eing different in the two groups. 𝜇1 ,𝑖,𝐸 was fixed, and 𝜇2 ,𝑖,𝐸 was varied
uch that the difference 𝜇2 ,𝑖,𝐸 − 𝜇1 ,𝑖,𝐸 ( 𝜀 𝐺 ) was one of {−0 . 2 𝑑, 0 , +0 . 2 𝑑}
here 𝑑 = 𝜇1 ,𝑖,𝐸 − 𝜇1 ,𝑖, ¬𝐸 . 0 is considered the reference level, where the
bnormal Gaussians are the same in the two groups. 𝜇𝑔,𝑖, ¬𝐸 were kept
he same in the two groups. Hence, when 𝜀 𝐺 = −0 . 2 𝑑, the abnormal
iomarker levels are closer to the normal biomarker levels in Group
 than in Group 1. This results in Group 2 biomarkers being weaker
han their Group 1 counterparts when 𝜀 𝐺 = −0 . 2 𝑑 and stronger when
 𝐺 = +0 . 2 𝑑. The number of subjects in Group 2 was kept a constant at
00, while the subjects in Group 1 increased from 100 to 900. 𝜀 𝑂 be-
ween the two groups was fixed at 0.4. We again generated 50 random
epetitions of the simulated datasets, and reported mean and standard
eviation of 𝜀 𝑆 for coupled DEBM, co-init DEBM and DEBM. 
These experiments were used to evaluate the different approaches
entioned in Section 2 and select the best method for analyzing the
ffect of APOE alleles in AD progression. 
.2. Studying the effect of APOE 
We considered the baseline measurements from 417 CN, 235 MCI
onverters and 342 AD subjects in ADNI1, ADNIGO and ADNI2 studies. 2 
he MCI converters are subjects who had MCI at baseline but converted
o AD within 3 years of baseline measurement. We excluded subjects
ith significant memory concerns (without a diagnosis of AD or MCI)
nd MCI non-converters in our experiments to select a more phenotyp-
cally homogeneous group of subjects with prevalent or incident AD. In
ach of the experiments, the dataset was divided into three groups ( 𝜀 2
arriers, homozygous 𝜀 3 carriers, and 𝜀 4 carriers) based on the subject’s
POE carriership ( van der Lee et al., 2018 ). Subjects with APOE 𝜀 2 , 4
n = 34) were not included in either group because of the presence of
V. Venkatraghavan, S. Klein, L. Fani et al. NeuroImage 227 (2021) 117646 
Table 1 
Demographics for the used population. 2 ⋆ represents the subjects with APOE 
alleles 𝜀 2 , 2 and 𝜀 2 , 3 . 33 represents the subjects with reference APOE allele 𝜀 3 , 3 . 
⋆ 4 represents the subjects with APOE alleles 𝜀 3 , 4 and 𝜀 4 , 4 . Subjects with both 
𝜀 2 and 𝜀 4 alleles were excluded from this study (n = 34). Edu. is an abbreviation 
used for Education. 
Demographics 
Diagnosis CN MCIc AD 
𝑛 417 235 342 
APOE 2 ⋆ /33/ ⋆ 4 57/244/110 6/66/156 12/101/219 
Sex M/F 209∕208 145∕90 189∕153 
Age [yrs.] ( 𝜇 ± 𝜎) 74 . 8 ± 5 . 7 73 . 7 ± 7 . 0 75 . 0 ± 7 . 8 
Edu [yrs.] ( 𝜇 ± 𝜎) 16 . 3 ± 2 . 7 15 . 9 ± 2 . 7 15 . 2 ± 3 . 0 
Table 2 
Biomarker availability in number of subjects in the APOE based groups of 𝜀 2 
carriers, homozygous 𝜀 3 carriers, and 𝜀 4 carriers. 
Biomarker availability 
Biomarker 𝜀 2 carriers 
( 𝑁 = 75) 
Homozygous 𝜀 3 
carriers ( 𝑁 = 411) 
𝜀 4 carriers 
( 𝑁 = 485) 
Imaging 74 408 481 
ABETA 57 301 357 
PTAU 57 301 357 
TAU 57 299 348 
NG 21 113 131 
NFL 23 118 137 
MMSE 75 411 485 
































































































g  Subject demographics and their APOE carrierships are summarized
n Table 1 . The modalities considered were structural imaging biomark-
rs, biomarkers extracted from cerebrospinal fluid (CSF), and cogni-
ive biomarkers. Structural imaging biomarkers were obtained from T1-
eighted MRI acquired at 1.5T or 3T. Details of the MRI acquisition
rotocols of ADNI can be found in Jack Jr. et al., 2008, 2015 . 
Imaging biomarkers were estimated from T1-weighted MRI scans
nalysed with FreeSurfer software v6.0 cross-sectional stream and out-
uts were visually checked. We assumed a symmetric pattern of atro-
hy in AD and averaged imaging biomarkers between the left and right
emisphere. 
Experiment 3: For this experiment, the selected imaging biomarkers
ere: hippocampal volume, volume of the entorhinal cortex, fusiform
yrus volume, middle-temporal gyrus volume, precuneus volume, to-
ether with whole brain volume and volume of the ventricles ( Archetti
t al., 2019; Frisoni et al., 2010; Vemuri and Jack, 2010 ). The se-
ected CSF based biomarkers were: CSF concentrations of Amyloid-
42 (ABETA), total Tau (TAU) and phosphorylated Tau 181 (PTAU) pro-
eins ( Blennow and Hampel, 2003; Blennow et al., 2010 ), Neuro-
ranin ( Thorsell et al., 2010 ) and Neurofilament light chain ( Jin et al.,
019; de Wolf et al., 2020 ). Mini mental state examination (MMSE) and
lzheimer’s Disease Assessment Scale - Cognitive (13 items) (ADAS13)
ere used as cognitive biomarkers. The availability of these multimodal
iomarkers in the ADNI database is summarized in Table 2 . 
We downloaded the CSF measurements from the ADNI database.
he measurements of ABETA, TAU and PTAU had been made using
he microbead-based multiplex immunoassay, the INNO-BIA AlzBio3
UO ( Olsson et al., 2005 ). The measurement of NFL had been made with
nzyme-linked immunosorbent assay NF-light ELISA kit ( Mattsson et al.,
017 ). NG had been measured by electrochemiluminescence technol-
gy (Meso Scale Discovery) using a monoclonal antibody specific for
G (Ng7) for coating together with a detector antibody polyclonal neu-
ogranin anti-rabbit (ab 23570, Upstate) ( Portelius et al., 2015 ). As de-
cribed previously in Venkatraghavan et al. (2019a) , the TAU and PTAU
easurements were transformed to logarithmic scales to make the dis-
ributions less skewed and more suitable for DEBM analysis. 5 The volumes of the selected regions were regressed with age, sex and
ntra-cranial volume (ICV) and the effects of these factors were subse-
uently corrected for, before being used as biomarkers. The effects of
ge and sex were regressed out of CSF features, whereas effects of age,
ex and education were regressed out of cognitive scores. 
For the 12 selected biomarkers, we estimated the disease timelines in
he three aforementioned groups using the method selected after simu-
ation experiments. We studied the positional variance of the estimated
rderings by creating 100 bootstrapped samples of the data. In order
o evaluate if the estimated orderings in the three groups were signif-
cantly different from one another, we used permutation testing and
stimated the distribution of the Kendall’s Tau distance under the null
ypothesis. To compute this distribution, we generated 10,000 random
ermutations of the three groups. We then computed the one-sided 𝑝 -
alues for the actual Kendall’s Tau distances between the orderings of
he three groups, calculated as the proportion of sampled permutations
here the distance was greater than or equal to the actual distance, and
sing Bonferroni correction to account for multiple testing. 
Experiment 4: In this experiment, we validated the disease stage
Υ𝑗 ) by computing its correlation with the subjects’ MMSE and ADAS13
alues. We used a 10-fold cross validation, where the training set was
sed to estimate the disease timeline in the aforementioned groups and
he test subjects’ disease stage was evaluated by placing them on this
isease timeline. We used the volume-based and CSF-based biomarkers




Experiment 1: Fig. 4 (a) and (b) show the ordering errors ( 𝜀 𝑆 ) in
roup 1 of the simulation datasets for DEBM, coupled DEBM and co-
nit DEBM as a function of number of subjects in Group 1, when 𝜀 𝑂 
etween the two groups changes from 0 to 1. Fig. 4 (c)–(e) show 𝜀 𝑆 in
roup 2 of the simulation datasets for the aforementioned methods, as a
unction of number of subjects in Group 1. In our experiments, Group 1
ataset remains the same while Group 2 dataset changes as 𝜀 𝑂 increase.
ence DEBM results do not change with change in 𝜀 𝑂 in Fig. 4 (a) and
b), whereas in Fig. 4 (c), DEBM results do not change with increase in
umber of subjects in Group 1. 
It can be seen that both coupled-training methods (i.e., co-init DEBM
nd coupled DEBM) outperform the default method of independently
raining DEBM models. It can also be observed that in both co-init DEBM
nd coupled DEBM the ordering errors decrease as 𝜀 𝑂 increases and
hat co-init DEBM outperforms coupled DEBM for lower values of 𝜀 𝑂 ,
hereas the performance is on par with coupled DEBM for higher values
f 𝜀 𝑂 . 
Experiment 2: Fig. 5 (a) and (b) show 𝜀 𝑆 in Group 1 and Fig. 5 (c)–
e) show the same in Group 2, when varying 𝜀 𝐺 . Even with 𝜀 𝐺 ≠ 0 , cou-
led training (i.e., co-init DEBM and coupled DEBM) outperformed the
efault method of independently training DEBM models. Co-init DEBM
howed negligible change in the errors when 𝜀 𝐺 ≠ 0 . The performance
f coupled DEBM in Group 1 worsened for 𝜀 𝐺 = +0 . 2 𝑑 ( Fig. 5 (a)) and
n Group 2 for 𝜀 𝐺 = −0 . 2 𝑑 ( Fig. 5 (d)). 
.2. Studying the effect of APOE 
The results in Experiments 1 and 2 show that the performance of
o-init DEBM is more accurate and robust than coupled DEBM in most
cenarios. We hence analyzed Experiments 3 and 4 using co-init DEBM.
Experiment 3: Fig. 6 shows orderings of CSF, global cognition and
olumetric biomarkers in the APOE based groups of 𝜀 2 carriers, homozy-
ous 𝜀 3 carriers, and 𝜀 4 carriers along with their uncertainty estimates.
t can be seen that the uncertainty of the ordering in the 𝜀 2 carriers
roup was high. Despite this uncertainty, some biomarkers (i.e. MMSE,
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Fig. 4. Experiment 1: The effect of 𝜀 𝑂 (the difference in groundtruth event orderings in the two groups) on the performance of the proposed methods. The shaded 
region in these plots represents standard deviation of the error in estimation of the proposed methods in 50 random iterations of simulations. The plots in (a) and (b) 
show the ordering errors in Group 1 using Coupled DEBM and Co-init DEBM with independent DEBM shown in both (a) and (b), as a function of number of subjects 
in Group 1. The plots in (c), (d) and (e) show the ordering errors in Group 2 using independent DEBM, Coupled DEBM and Co-init DEBM respectively as a function 































G and PTAU) seem to occur earlier than the other biomarkers in this
roup. 
In the homozygous 𝜀 3 carrier group, ABETA was very prominently
he earliest biomarker, followed by cognitive scores of MMSE and
DAS13. Among the CSF biomarkers, PTAU followed immediately af-
er ABETA, which was inturn followed by TAU. NFL and NG were late
iomarkers. Among the structural biomarkers, volumes of fusiform and
iddle-temporal gyri were the first to become abnormal, followed by
entricular volume and wholebrain volume. Hippocampus, precuneus
nd entorhinal volumes were late biomarkers in this group. 
In the 𝜀 4 carrier group, the CSF biomarkers followed a pattern that
as similar to that of the homozygous 𝜀 3 carrier group. The cognitive
iomarkers were early biomarkers in this group as well. However the
rdering in structural biomarkers was very different from that in the
omozygous 𝜀 3 carrier group. Hippocampus and entorhinal volumes6 ere early biomarkers in this group, followed by middle-temporal and
usiform gyri volumes. Wholebrain, ventricular and precuneus volumes
ere late biomarkers. 
The ordering of the 𝜀 2 carrier group was significantly different from
hat of the homozygous 𝜀 3 carrier group ( 𝑝 = 0 . 0156 , after Bonferroni
orrection for multiple testing). Similarly, the orderings for the other
wo groups were significant as well: 𝑝 = 0 . 0147 for the difference be-
ween 𝜀 2 carrier group and 𝜀 4 carrier group and 𝑝 = 0 . 0003 for the
ifference between the homozygous 𝜀 3 carrier group and 𝜀 4 carrier
roup. 
Experiment 4: The variation of MMSE and ADAS13 scores with re-
pect to the estimated disease stages has been plotted in Fig. 7 , for all
hree groups. The patient stages showed a significant correlation with
oth MMSE and ADAS13 scores. The correlation coefficients were also
omparable in the three groups. 
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Fig. 5. Experiment 2: The effect of 𝜀 𝐺 (difference in abnormal biomarker levels in the two groups), on the performance of the proposed methods. The shaded region 
represents standard deviation of the error in 50 random iterations. The plots in (a) and (b) show the ordering errors in Group 1 using Coupled DEBM and Co-init 
DEBM with independent DEBM shown in both (a) and (b), as a function of number of subjects in Group 1. The plots in (c), (d) and (e) show the ordering errors in 

















































t  . Discussion 
DEBM models have been shown to be effective in determining the
emporal cascade of biomarker abnormality as AD progresses, from
ross-sectional data. In this work, we introduced a novel concept of split-
ing the different steps of DEBM into group-specific and group-aspecific
arts for coupled training in stratified population. We considered two
ovel variations to split the steps of DEBM in this manner and through
horough experimentation in simulation datasets we observed that co-
nit DEBM helps in obtaining more accurate orderings in a stratified
opulation. Using this method, we estimated the biomarker cascades in
D progression with 𝜀 2 alleles, homozygous 𝜀 3 alleles, and 𝜀 4 alleles of
POE , based on cross-sectional ADNI data. While the findings in the ho-
ozygous 𝜀 3 carrier and 𝜀 4 carrier groups fit the current understanding
f progression of AD with high-confidence, the finding in the 𝜀 2 carrier
roup shows evidence for an alternative pathway (with relatively low
onfidence). In this section, we discuss the insights provided by the sim-
lation experiments ( Section 5.1 ) used for method selection as well as
he insights into the AD progression pathways provided by our experi-
ents on the ADNI dataset ( Section 5.2 ). 
.1. Choice of the method 
Coupled DEBM and co-init DEBM both split DEBM into group-
pecific and group-aspecific steps for coupled training of an EBM in
tratified populations. Experiment 1 and 2 showed that coupled train-7 ng of the group-aspecific parts of DEBM and independently training
he group-specific parts of DEBM results in more accurate orderings in
he groups better than the default approach of independently training a
EBM model in each group. 
While splitting DEBM into group-specific and group-aspecific parts,
e started with the assumption that the latent true normal and abnor-
al biomarker distributions in the groups are either same or similar.
he difference between co-init DEBM and coupled DEBM is that, co-
nit DEBM accounts for slight differences in the underlying biomarker
istributions between the groups whereas coupled DEBM does not. 
The simulation dataset generated in Experiment 1 had the same true
ormal and abnormal biomarker distributions in the different groups,
rom which the simulated subjects were randomly sampled, aligning
ell with the assumption of coupled DEBM. However, this did not re-
ult in overall better accuracies for coupled DEBM than that of co-init
EBM. Co-init DEBM was also more robust than coupled DEBM as its ac-
uracy was less dependent on 𝜀 𝑂 , the distance between the ground-truth
rderings in the two groups. 
Another observation in Experiment 1, which was rather counter-
ntuitive, was that the errors made by the co-init and coupled DEBM
odels decreased as the distance between the ground-truth orderings
n the two groups increased. When the orderings are further apart, the
ombined biomarker distributions in CN and AD groups have a larger
verlap. The non-overlapping initialization (before the GMM optimiza-
ion) thus results in the normal and abnormal distributions to be fur-
her apart. We hypothesize that this results in a better estimation of
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Fig. 6. Experiment 3: Orderings of CSF, global cognition and volumetric 
biomarkers in the APOE based groups of 𝜀 2 carriers, homozygous 𝜀 3 carriers, 
and 𝜀 4 carriers along with their uncertainty estimates. Uncertainty in the esti- 
mation of the ordering was measured by 100 repetitions of bootstrapping, in 
the three APOE based groups. The color-map is based on the number of times 
a biomarker is at a position in 100 repetitions of bootstrapping. The number of 
subjects in the three groups were 75, 411 and 485 respectively. The orderings 































































8 he mixing parameters during GMM optimization and in-turn resulted
n more accurate orderings, as mixing-parameters are dependent on the
iomarker’s position in the ordering. 
In Experiment 2, we checked the performance of our approaches
hen the assumption (true normal and abnormal biomarker distribu-
ions being same across groups) is violated in the dataset. This experi-
ent showed that the orderings obtained using co-init DEBM are more
obust to differences between the abnormal Gaussians across groups
han those obtained with coupled DEBM. With coupled DEBM, the error
ncreased in the group with weaker biomarkers i.e., Group 1 in the case
f 𝜀 𝐺 = +0 . 2 𝑑 and Group 2 in the case of 𝜀 𝐺 = −0 . 2 𝑑. This shows that
oupled DEBM introduces a systematic bias in the estimation of ordering
hat is detrimental to the group with weaker biomarkers. Co-init DEBM
lso showed a similar bias, but to a much lesser extent. 
We hence selected co-init DEBM as the preferred approach for split-
ing and performed our analysis on ADNI dataset using this approach.
e expect that this idea of splitting DEBM into group-specific and
roup-aspecific parts can be easily extended to the EBM introduced
y Fonteijn et al. (2012) . 
.2. Cascade of biomarker changes in the APOE based groups 
Dividing the total population into groups based on APOE car-
iership enabled us to create more phenotypically homogeneous
roups ( Weintraub et al., 2019 ), each with potentially specific disease
rogression timeline. In this section, we discuss our results in these
POE carriership based groups. 
Our findings show that the three APOE -carriership based groups
ave significantly different temporal cascades of disease progression.
his suggests that the underlying pathways of progression are different
or the three genotypes. Among the CSF biomarkers in the homozygous
 3 carrier and the 𝜀 4 carrier groups, ABETA abnormality is the earliest
iomarker event followed by PTAU. This fits current understanding of
D progression ( Bloom, 2014 ). It also confirms the need for preventing
he accumulation of ABETA in high-risk patients. NFL and NG are late
iomarkers in the homozygous 𝜀 3 carrier and 𝜀 4 carrier groups, which
uggests that axonal ( Ashton et al., 2019 ) and synaptic ( Thorsell et al.,
010 ) degeneration do not occur until very late in the disease process in
hese groups. NG being abnormal after PTAU and TAU in the homozy-
ous 𝜀 3 carrier and 𝜀 4 carrier groups is also consistent with the previous
ndings that Tau mediates synaptic damage in AD ( Jadhav et al., 2015 ).
In the 𝜀 2 carrier group, we found that the abnormal NG and PTAU
re the earliest CSF events, even before ABETA becomes abnormal. This
ould hint at the existence of an alternative pathway for the formation
f tau tangles in the brain before ABETA accumulation, as suggested
n Weigand et al. (2019) , but needs more extensive validation. 
Among the volumetric biomarkers, Entorhinal cortex is one of the
arly biomarkers in the 𝜀 4 carrier group which is supported by the find-
ngs in Huijbers et al. (2014) , but is one of the last biomarkers to be-
ome abnormal in the homozygous 𝜀 3 carrier group. Ventricular vol-
me is a late biomarker in the 𝜀 4 carrier group but it becomes abnor-
al quite early in the homozygous 𝜀 3 carrier group as also observed
y Nestor et al. (2008) . Hippocampus volume is the earliest biomarker
n the 𝜀 4 carrier group, but is a relatively late biomarker in the ho-
ozygous 𝜀 3 carrier and 𝜀 2 carrier groups. This suggests that incidence
f hippocampal sparing AD ( Ferreira et al., 2017 ) could correlate with
POE carriership. 
The findings related to these orderings of biomarker events were
alidated by correlating the patient stages derived from these orderings
ith MMSE and ADAS13 scores. Patient stages of subjects in all three
roups, when used as test-subjects in a cross-validated manner, showed a
ignificant correlation ( 𝑝 < 0 . 001 ) with these scores. These correlations
alidate our findings and suggest that these genotype-specific disease
rogression timelines could be used for patient monitoring. 
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Fig. 7. Experim ent 4: Correlation of esti- 
mated disease stages with MMSE and ADAS 
scores in the APOE based groups of 𝜀 2 carriers, 
homozygous 𝜀 3 carriers, and 𝜀 4 carriers. The 
plot on top of each subfigure shows the prob- 
ability density function of the disease stages, 
and the plot on the right of each subfigure 
shows the probability density function of the 
cognitive score in the subfigure. The 2D plot 
in each subfigure shows the joint density func- 
tion of the two axes. The line in each subfigure 
shows the linear regression of MMSE / ADAS 
scores with the estimated disease stage and the 
shaded area around the line shows its 95% con- 
fidence interval. Figures (a),(c) and (e) depict 
correlation between MMSE score and obtained 
disease stages in the three APOE based groups. 
Figures (b), (d) and (f) depict correlation be- 
tween ADAS13 score and the obtained disease 











t  . Conclusion and future work 
We conclude that co-init DEBM provides the best accuracy and ro-
ustness when estimating orderings in stratified populations. Future
ork on co-init DEBM can focus on extending the approach for high-
imensional imaging biomarkers ( Venkatraghavan et al., 2019b ). This9 ork also provides groundwork for extending the method towards
ypothesis-free, data-driven stratification of phenotypes. 
We gained new insights into the disease progression timeline of AD
n the APOE based groups of 𝜀 2 carriers, homozygous 𝜀 3 carriers, and
 4 carriers. While we observed that the estimated disease progression
imelines in the 𝜀 4 carrier and the homozygous 𝜀 3 carrier groups fit




























































































































he current understanding of AD progression with high confidence, the
stimated timelines in the 𝜀 2 carrier group may suggest an alternative
athway for the formation of tau tangles in the brain before amyloid
accumulation, albeit with relatively low condence. We expect that
hese genotype-specific disease progression timelines will benefit patient
onitoring in the future, and may help optimize selection of eligible
ubjects for clinical trials. 
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